公司概述
Align Technology, Inc. operates as a prominent provider of orthodontic solutions, specifically offering Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners alongside related services across the United States, Switzerland, and international markets. The company functions within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, which implies a focus on specialized medical devices and diagnostic equipment used in professional dental and orthodontic practices. As of the latest reporting period, the enterprise holds a market capitalization of $12.50B, generated annual revenue of $4.03B, and employs a workforce of 20,290 individuals. These valuation and revenue figures indicate that Align Technology commands a significant position in its niche market, reflecting substantial investor confidence and a robust operational footprint capable of supporting a large-scale global distribution network.
财务健康
The company reported a trailing twelve-month revenue of $4.03B, with net income reaching $410.35M and EBITDA standing at $851.35M. The substantial gap between the total revenue of $4.03B and the net income of $410.35M reveals a distinct cost structure where operating expenses, including cost of goods sold, research and development, and administrative costs, consume a significant portion of top-line growth before reaching the bottom line. Free cash flow for the period was $483.69M, a metric that signifies strong financial flexibility allowing the company to fund operations, invest in technology, or manage debt obligations without relying on external financing. The company maintains a gross margin of 69.8%, indicating high pricing power and efficient production or procurement of its aligner systems; an operating margin of 22.4% suggests effective control over overhead and administrative expenses; and a profit margin of 10.2% demonstrates the final profitability available to shareholders after all costs are deducted. Regarding liquidity and leverage, the company holds $1.09B in cash against $114.45M in debt, while the debt-to-equity ratio stands at 2.83, suggesting a leveraged balance sheet where equity capital is a smaller base relative to the debt load. Despite the leverage, the current ratio of 1.36 indicates adequate short-term liquidity, as current assets exceed current liabilities by a comfortable margin. Furthermore, the return on equity of 10.4% and return on assets of 6.9% provide insight into management effectiveness, showing that the company generates moderate returns on the capital invested by shareholders and utilized in its asset base.
估值评估
Align Technology trades with a trailing twelve-month P/E ratio of 30.89 and a forward P/E of 14.22. The significant difference between these two multiples implies that the market expects earnings to grow substantially in the coming years, as the forward multiple is less than half of the trailing multiple, suggesting a belief that current earnings are not representative of future performance. The price-to-book ratio is recorded at 3.08, which indicates that the market values the company at a significant premium over its net book value, reflecting the intangible assets and brand strength inherent in its intellectual property portfolio. Alternative valuation metrics such as the price-to-sales ratio of 3.10 and the EV/EBITDA of 13.46 suggest that investors are willing to pay a multiple of earnings before interest, taxes, depreciation, and amortization that is moderate for a high-growth healthcare firm, while the P/S multiple highlights the revenue quality relative to market price. Regarding trading ranges, the stock has a 52-week high of $208.31 and a 52-week low of $122.00. To calculate the current position relative to this range, one must note the distance from the low; however, without the exact current share price, the specific percentage below the high or above the low cannot be precisely calculated from the provided facts alone, but the wide range of $86.31 between the high and low demonstrates significant volatility. The beta value is 1.81, meaning the stock is expected to be 81% more volatile than the broader market, indicating that price movements in Align Technology will likely exceed those of the overall market index during periods of volatility.
Growth & Income
The company demonstrated a revenue growth rate of 5.3% year-over-year, while earnings growth reached 35.6% year-over-year. The fact that earnings are growing at a rate more than six times faster than revenue implies significant margin expansion or a return to profitability that was previously suppressed, rather than simple top-line volume increases. Align Technology does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which explains that the company chooses to reinvest all earnings into growth initiatives, research, and expansion rather than distributing cash to shareholders. This strategy aligns with a non-dividend payer profile where capital allocation focuses on long-term market share acquisition and technological advancement rather than immediate income generation. Consequently, the overall growth and income profile is characterized by aggressive reinvestment and high earnings acceleration, prioritizing capital appreciation and operational scaling over current income distribution for investors seeking growth exposure in the medical device sector.